2019
Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Patients With Knee Osteoarthritis
Smith KC, Losina E, Messier SP, Hunter DJ, Chen AT, Katz JN, Paltiel AD. Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Patients With Knee Osteoarthritis. ACR Open Rheumatology 2019, 2: 26-36. PMID: 31943972, PMCID: PMC6957917, DOI: 10.1002/acr2.11090.Peer-Reviewed Original ResearchKnee osteoarthritisMedicare plansIntensive dietKnee OA treatmentIncidence of comorbiditiesCommercial insurance plansHealth promotion interventionsMedicare-eligible individualsOsteoarthritis Policy ModelTotal knee replacementCommercial plansObese patientsOpioid useMore patientsExercise programArthritis trialsKnee replacementMedicare Advantage plansOsteoarthritisOA treatmentBudget impactMedical expendituresInsurance plansPatientsDietCost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis
Losina E, Smith KC, Paltiel AD, Collins JE, Suter LG, Hunter DJ, Katz JN, Messier SP. Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. Arthritis Care & Research 2019, 71: 855-864. PMID: 30055077, PMCID: PMC6349519, DOI: 10.1002/acr.23716.Peer-Reviewed Original ResearchMeSH KeywordsAgedCaloric RestrictionComparative Effectiveness ResearchComputer SimulationCost-Benefit AnalysisExerciseFemaleHealth Care CostsHealthy LifestyleHumansMaleMiddle AgedModels, EconomicMonte Carlo MethodObesityOsteoarthritis, KneeQuality of LifeQuality-Adjusted Life YearsRisk Reduction BehaviorTime FactorsTreatment OutcomeWeight LossConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesKnee osteoarthritisObese patientsIntensive dietSocietal perspectiveHealth care sector perspectiveLifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioIDEA trialPain reductionUsual careExercise programArthritis trialsTreatment strategiesLifetime horizonClinical practicePatientsOsteoarthritisOverweightQALYHealth care sectorWeight reductionDiet
2017
The Inclusion Body Myositis Registry at Yale: A growing information database and practical tool for researchers, clinicians, and patients
Cotzomi E, Petschke K, O'Connor K, Paltiel A. The Inclusion Body Myositis Registry at Yale: A growing information database and practical tool for researchers, clinicians, and patients. Muscle & Nerve 2017 DOI: 10.1002/mus.25774.Peer-Reviewed Original ResearchA Flow-Based Model of the HIV Care Continuum in the United States
Gonsalves GS, Paltiel AD, Cleary PD, Gill MJ, Kitahata MM, Rebeiro PF, Silverberg MJ, Horberg M, Abraham AG, Althoff KN, Moore R, Bosch RJ, Tang T, Hall HI, Kaplan EH. A Flow-Based Model of the HIV Care Continuum in the United States. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 548-553. PMID: 28471841, PMCID: PMC5533168, DOI: 10.1097/qai.0000000000001429.Peer-Reviewed Original ResearchConceptsViral suppressionAntiretroviral therapyHIV careNorth American AIDS Cohort CollaborationProportion of HIVHIV care continuumCohort CollaborationHIV diagnosisAntiretroviral treatmentVirological dataCare continuumFlow of patientsDisease controlPatientsCareAverage timeHIVTherapyLaboratory resultsMonthsSuppressionYearsDiagnosisIndividualsPrevention
2016
Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa
Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP. Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLOS ONE 2016, 11: e0165614. PMID: 27906986, PMCID: PMC5131994, DOI: 10.1371/journal.pone.0165614.Peer-Reviewed Original ResearchConceptsTB/HIVTB/HIV controlHIV screeningHIV controlRural South AfricaLife yearsMonths of IPTMost life yearsHigh-incidence settingsWidespread prevalenceCost-effectiveness resultsProbabilistic sensitivity analysesHIV transmissionHigh burdenTreatment coverageUnknown patientsHIVHealthcare accessDrug resistanceActive casesMonthsLifetime usePatientsYearsScreeningSurvival benefits of antiretroviral therapy in Brazil: a model‐based analysis
Luz PM, Girouard MP, Grinsztejn B, Freedberg KA, Veloso VG, Losina E, Struchiner CJ, MacLean RL, Parker RA, Paltiel AD, Walensky RP. Survival benefits of antiretroviral therapy in Brazil: a model‐based analysis. Journal Of The International AIDS Society 2016, 19: 20623. PMID: 27029828, PMCID: PMC4814587, DOI: 10.7448/ias.19.1.20623.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHIV-positive patientsSurvival benefitART initiationEligible HIV-positive patientsProvision of ARTDramatic survival benefitsSubsequent ART regimensMean CD4 countLife expectancyNumber of patientsProjected life expectancyART regimensCD4 countHigher CD4HIV diseaseRegimen efficacyLife expectancy increasesEra 1PatientsTherapyNational programExpectancyCD4Regimens
2015
Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US
Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Research & Clinical Practice 2015, 16: 207-218. PMID: 26651525, PMCID: PMC4718767, DOI: 10.1080/15284336.2015.1123942.Peer-Reviewed Original ResearchConceptsGeneric antiretroviral therapyAntiretroviral therapyProbabilistic sensitivity analysesTreatment changesFirst-line ART regimensMore treatment changesComparative effectiveness trialTwo-arm trialImproved health outcomesTwo-pillART regimensHIV careART failureEffectiveness trialTrial completionRNA suppressionHealth outcomesFuture patientsPatientsCost-effective strategyTrialsRegimenRegimensHIVTherapyDemographic and clinical features of inclusion body myositis in north America
Paltiel AD, Ingvarsson E, Lee DK, Leff RL, Nowak RJ, Petschke KD, Richards-Shubik S, Zhou A, Shubik M, O'Connor KC. Demographic and clinical features of inclusion body myositis in north America. Muscle & Nerve 2015, 52: 527-533. PMID: 25557419, PMCID: PMC4869122, DOI: 10.1002/mus.24562.Peer-Reviewed Original ResearchConceptsInclusion body myositisBody myositisDaily livingComposite functional indexLarger patient populationWeakness of armsDisease durationClinical featuresInitial diagnosisMean agePatient populationFemale ratioClinical managementClinical trialsOutcome measuresFirst symptomsFunctional indexEarly symptomsNatural historyMean timeSelf-report surveyMyositisPatientsSymptomsDiagnosisThe Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy
Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP, Freedberg KA, Losina E. The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy. Clinical Infectious Diseases 2015, 60: 1102-1110. PMID: 25583979, PMCID: PMC4366583, DOI: 10.1093/cid/ciu1159.Peer-Reviewed Original ResearchConceptsDaily ART adherenceAnnual drug costsART adherenceLA-ARTAntiretroviral therapyDrug costsART-naive patientsDaily oral ARTHIV RNA suppressionSecond-line therapyFirst-line therapyFirst-line regimensHuman immunodeficiency virusDaily ARTOverall life expectancyHIV patientsAdherent patientsAvailable regimensART failureImmunodeficiency virusClinical rolePatientsRNA suppressionTherapyAnnual cost
2014
Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa
Ouattara EN, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, Moh R, Walensky RP, Danel C, Paltiel AD, Eholié SP, Freedberg KA, Anglaret X. Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 66: 294-302. PMID: 24732870, PMCID: PMC4146647, DOI: 10.1097/qai.0000000000000166.Peer-Reviewed Original ResearchConceptsThird-line antiretroviral therapySecond-line antiretroviral therapyIncremental cost-effectiveness ratioAntiretroviral therapyAdherence reinforcementClinical impactSecond-line ART failureLifetime incremental cost-effectiveness ratioRaltegravir-based regimenSecond-line regimenTen-year survivalSubstantial survival benefitCost-effectiveness ratioPrimary outcomeSurvival benefitART failureDrug costsImmediate switchRegimenPatientsTherapyReinforcement interventionSaharan AfricaSurvivalSub-Saharan Africa
2013
The Survival Benefits of Antiretroviral Therapy in South Africa
April MD, Wood R, Berkowitz BK, Paltiel AD, Anglaret X, Losina E, Freedberg KA, Walensky RP. The Survival Benefits of Antiretroviral Therapy in South Africa. The Journal Of Infectious Diseases 2013, 209: 491-499. PMID: 24307741, PMCID: PMC3903379, DOI: 10.1093/infdis/jit584.Peer-Reviewed Original ResearchConceptsSecond-line antiretroviral therapyAntiretroviral therapySurvival benefitAIDS Complications-International modelTotal survival benefitT-cell countsHuman immunodeficiency virusART initiationART rolloutUntreated patientsImmunodeficiency virusART availabilitySurvival differencesSuppressive efficacyCohortPatientsTherapyTotal numberRetention ratePersonsBenefitsCost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples
Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Wang L, McCauley M, Gamble T, Seage GR, Cohen MS, Freedberg KA. Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. New England Journal Of Medicine 2013, 369: 1715-1725. PMID: 24171517, PMCID: PMC3913536, DOI: 10.1056/nejmsa1214720.Peer-Reviewed Original ResearchConceptsEarly antiretroviral therapyHuman immunodeficiency virusAntiretroviral therapySerodiscordant couplesHIV transmissionHIV Prevention Trials Network 052 studyIncremental cost-effectiveness ratioCost-effectiveness ratioResource-limited settingsHIV infectionClinical benefitImmunodeficiency virusHIV treatmentLonger survivalOpportunistic diseasesEarly initiationFive yearsLifetime outcomesPublic healthSuch personsPatientsPeriodTherapyInfectionDisease
2011
Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing
April MD, Chiosi JJ, Paltiel AD, Sax PE, Walensky RP. Projected Survival Gains from Revising State Laws Requiring Written Opt-in Consent for HIV Testing. Journal Of General Internal Medicine 2011, 26: 661-667. PMID: 21286837, PMCID: PMC3101973, DOI: 10.1007/s11606-011-1637-5.Peer-Reviewed Original ResearchConceptsPotential survival gainsSurvival gainHIV testingDiagnosis rateAnnual HIV incidenceProportion of HIVUndiagnosed HIV prevalenceAnnual HIV diagnosis ratesHIV diagnosis ratesHIV incidenceHIV prevalenceEarly diagnosisHIVDisease controlLYGSurveillance dataAdult personsConsentConsent methodsPersonsPatientsConsent lawsBackgroundAlthoughDesignWeObjectiveTo
2009
Medical decision making in patients with knee pain, meniscal tear, and osteoarthritis
Suter LG, Fraenkel L, Losina E, Katz JN, Gomoll AH, Paltiel AD. Medical decision making in patients with knee pain, meniscal tear, and osteoarthritis. Arthritis & Rheumatism 2009, 61: 1531-1538. PMID: 19877094, PMCID: PMC2804854, DOI: 10.1002/art.24893.Peer-Reviewed Original ResearchConceptsArthroscopic partial meniscectomyMeniscal tearsKnee painInternational Knee Documentation Committee scoreMagnetic resonance imaging (MRI) indicatorsObtainable clinical informationDegenerative meniscal tearsIndividuals ages 45Mean incremental gainIKDC scoreNonoperative managementAge 45Preoperative informationPartial meniscectomyClinical informationOsteoarthritisPainTearsLower likelihoodHigher likelihoodAlternative thresholdsMedical decisionsScoresIncremental gainPatients
2008
Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival
Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA. Scaling Up Antiretroviral Therapy in South Africa: The Impact of Speed on Survival. The Journal Of Infectious Diseases 2008, 197: 1324-1332. PMID: 18422445, PMCID: PMC2423492, DOI: 10.1086/587184.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyEligible human immunodeficiency virusEffective antiretroviral therapyHuman immunodeficiency virusNeed of therapyHIV infectionImmunodeficiency virusPatient outcomesAdult cohortDeath rateART scaleTherapyCumulative deathsTreatment slotsDeathRapid scaleHIVPatientsCohortInfectionMortality
2007
Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model
Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model. Journal Of Allergy And Clinical Immunology 2007, 120: 1146-1152. PMID: 17904628, PMCID: PMC3476046, DOI: 10.1016/j.jaci.2007.07.055.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness ratioSevere asthmaEvent ratesSevere allergic asthmaQuality-adjusted monthsAllergic asthmaMost patientsAlternative medicationsHigher acquisition costUS FoodAsthmaDrug AdministrationLife yearsPatientsIncremental costDisease managementOmalizumabCost-effective optionTreatmentAcquisition costsEconomic outcomesCorticosteroidsMedicationsClinicians
2006
Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients
Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E. Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s113-s118. PMID: 17133193, DOI: 10.1097/01.qai.0000248334.52072.25.Peer-Reviewed Original ResearchConceptsStandard careNursing interventionsClinical trialsLong-term survival benefitIncremental cost-effectiveness ratioCohort of HIVQuality-adjusted life yearsLifetime medical costsCost-effectiveness ratioVirologic suppressionAntiretroviral therapyViral suppressionAntiretroviral medicationsHIV diseaseSurvival benefitClinical outcomesAdherence interventionsAntiretroviral adherenceMedical costsLife yearsModest effectivenessPatientsInterventionAdherenceHIV
2005
Cost Advantage of Dual-Chamber Versus Single-Chamber Cardioverter-Defibrillator Implantation
Goldberger Z, Elbel B, McPherson CA, Paltiel AD, Lampert R. Cost Advantage of Dual-Chamber Versus Single-Chamber Cardioverter-Defibrillator Implantation. Journal Of The American College Of Cardiology 2005, 46: 850-857. PMID: 16139136, DOI: 10.1016/j.jacc.2005.05.061.Peer-Reviewed Original ResearchConceptsElectrophysiologic studySingle-chamber devicesUpgrade rateMost patient populationsSingle-chamber ICDCardioverter-defibrillator implantationSingle university hospitalElectrophysiologic testingRetrospective reviewPatient populationUniversity HospitalDevice selectionInitial implantationPatientsResource utilization costsPerson costsImplantation strategyClinical needICDImplantationExpensive strategyCostly strategyPotential needUtilization costsICD/Routine human immunodeficiency virus testing: An economic evaluation of current guidelines
Walensky RP, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, Paltiel AD. Routine human immunodeficiency virus testing: An economic evaluation of current guidelines. The American Journal Of Medicine 2005, 118: 292-300. PMID: 15745728, DOI: 10.1016/j.amjmed.2004.07.055.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioHIV prevalenceCurrent guidelinesHuman immunodeficiency virus (HIV) counselingMean quality-adjusted life expectancyHIV Screening ProgramQuality-adjusted life expectancyLife-sustaining careOverall participation rateCost-effectiveness analysisUndiagnosed infectionHIV screeningHIV counselingClinical effectsReferral guidelinesPrevention guidelinesInfected patientsScreening programDisease controlPrevalenceU.S. hospitalsScreening thresholdLife expectancyHIVPatientsAn Asthma Policy Model
Paltiel A, Kuntz K, Weiss S, Fuhlbrigge A. An Asthma Policy Model. International Series In Operations Research & Management Science 2005, 70: 659-693. DOI: 10.1007/1-4020-8066-2_26.Peer-Reviewed Original Research